Halozyme Therapeutics (HALO) Tops Q3 EPS by 42c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $112.45 +2.53%
Revenue Growth %: +36.2%
Financial Fact:
Product sales: 13.33M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +36.2%
Financial Fact:
Product sales: 13.33M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of $0.74, $0.42 better than the analyst estimate of $0.32. Revenue for the quarter came in at $209 million versus the consensus estimate of $189.72 million.
GUIDANCE:
Halozyme Therapeutics sees FY2022 revenue of $655-685 million, versus the consensus of $661.33 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- UBS cuts KOSPI target by nearly 10% to reflect higher rates
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
